OncoHost announced that it has been named a winner in the 2025 BIG Innovation Awards. The recognition, presented by the Business Intelligence Group, honors OncoHost in the “Healthcare” category.
OncoHost’s PROphet platform aims to provide reliable biomarkers that guide immunotherapy treatment decisions. In the current landscape, a lack of definitive biomarkers leaves clinicians without clear direction, increasing the risk of poor response. While thousands of clinical trials explore immunotherapy treatment options, progress in finding actionable biomarkers is limited. PROphet represents a next-generation solution to this challenge, delivering personalized insights to optimize therapeutic decisions and improve patient outcomes.
The platform’s initial commercialized test, PROphetNSCLC, is the first and only liquid biopsy standalone proteomics test on the market and the first AI-based blood test to guide first-line immunotherapy decisions in metastatic non-small cell lung cancer (NSCLC).
While initially validated in NSCLC, PROphet has shown promise in predicting clinical benefit in melanoma, renal cell carcinoma (RCC), and HPV-associated malignancies, triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and colorectal cancer, suggesting the potential of a plasma-proteomics signature for multiple cancer applications.
In addition, OncoHost is developing the PROphetirAE test designed to predict immune-related adverse events prior to the start of treatment. By identifying patients who are more likely to experience substantial toxicities, this model presents a viable way to improve patient care by enabling better treatment decisions.
Organizations from across the globe submitted their recent innovations for consideration in the BIG Innovation Awards. Winners were evaluated by a panel of seasoned business leaders and executives who considered creativity, measurable results, and overall impact in their selections.
